Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CCL3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CCL3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CCL3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CCL3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CCL3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206323 | Thyroid | ATC | gliogenesis | 127/6293 | 301/18723 | 1.07e-03 | 5.66e-03 | 127 |
GO:000268818 | Thyroid | ATC | regulation of leukocyte chemotaxis | 57/6293 | 122/18723 | 1.77e-03 | 8.71e-03 | 57 |
GO:005170222 | Thyroid | ATC | biological process involved in interaction with symbiont | 45/6293 | 94/18723 | 2.86e-03 | 1.30e-02 | 45 |
GO:000268519 | Thyroid | ATC | regulation of leukocyte migration | 90/6293 | 210/18723 | 3.11e-03 | 1.40e-02 | 90 |
GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
GO:00508483 | Thyroid | ATC | regulation of calcium-mediated signaling | 36/6293 | 73/18723 | 3.91e-03 | 1.70e-02 | 36 |
GO:00327608 | Thyroid | ATC | positive regulation of tumor necrosis factor production | 48/6293 | 103/18723 | 4.14e-03 | 1.76e-02 | 48 |
GO:004392211 | Thyroid | ATC | negative regulation by host of viral transcription | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
GO:19035576 | Thyroid | ATC | positive regulation of tumor necrosis factor superfamily cytokine production | 49/6293 | 107/18723 | 5.79e-03 | 2.34e-02 | 49 |
GO:007055513 | Thyroid | ATC | response to interleukin-1 | 63/6293 | 143/18723 | 5.82e-03 | 2.35e-02 | 63 |
GO:007167516 | Thyroid | ATC | regulation of mononuclear cell migration | 52/6293 | 115/18723 | 6.24e-03 | 2.50e-02 | 52 |
GO:00083472 | Thyroid | ATC | glial cell migration | 27/6293 | 53/18723 | 6.76e-03 | 2.69e-02 | 27 |
GO:01101492 | Thyroid | ATC | regulation of biomineralization | 45/6293 | 99/18723 | 9.34e-03 | 3.44e-02 | 45 |
GO:20004035 | Thyroid | ATC | positive regulation of lymphocyte migration | 19/6293 | 35/18723 | 9.36e-03 | 3.44e-02 | 19 |
GO:003434116 | Thyroid | ATC | response to interferon-gamma | 61/6293 | 141/18723 | 1.04e-02 | 3.79e-02 | 61 |
GO:00701672 | Thyroid | ATC | regulation of biomineral tissue development | 44/6293 | 97/18723 | 1.05e-02 | 3.81e-02 | 44 |
GO:007134614 | Thyroid | ATC | cellular response to interferon-gamma | 52/6293 | 118/18723 | 1.14e-02 | 4.06e-02 | 52 |
GO:0002573110 | Thyroid | ATC | myeloid leukocyte differentiation | 86/6293 | 208/18723 | 1.15e-02 | 4.11e-02 | 86 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0532314 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0532315 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
hsa0541745 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0541755 | Cervix | N_HPV | Lipid and atherosclerosis | 22/349 | 215/8465 | 7.28e-05 | 7.92e-04 | 6.19e-04 | 22 |
hsa0516312 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa0532310 | Liver | Cirrhotic | Rheumatoid arthritis | 38/2530 | 93/8465 | 1.52e-02 | 4.57e-02 | 2.82e-02 | 38 |
hsa0516313 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa0532311 | Liver | Cirrhotic | Rheumatoid arthritis | 38/2530 | 93/8465 | 1.52e-02 | 4.57e-02 | 2.82e-02 | 38 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa05142 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa0541742 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa051421 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa0541752 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL3 | SNV | Missense_Mutation | novel | c.123N>T | p.Gln41His | p.Q41H | P10147 | protein_coding | deleterious(0.01) | benign(0.049) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.131N>G | p.Gln44Arg | p.Q44R | P10147 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.73C>T | p.Leu25Phe | p.L25F | P10147 | protein_coding | tolerated(1) | benign(0.005) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.178C>T | p.Pro60Ser | p.P60S | P10147 | protein_coding | deleterious(0.02) | possibly_damaging(0.764) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
CCL3 | SNV | Missense_Mutation | rs773703371 | c.203G>A | p.Arg68Gln | p.R68Q | P10147 | protein_coding | deleterious(0) | possibly_damaging(0.842) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CCL3 | SNV | Missense_Mutation | novel | c.232N>A | p.Glu78Lys | p.E78K | P10147 | protein_coding | deleterious(0.03) | benign(0.021) | TCGA-DD-A73A-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | novel | c.273N>A | p.Ser91Arg | p.S91R | P10147 | protein_coding | deleterious(0) | benign(0.104) | TCGA-18-3414-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | rs190805628 | c.101G>C | p.Cys34Ser | p.C34S | P10147 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD |
CCL3 | SNV | Missense_Mutation | novel | c.106A>T | p.Ser36Cys | p.S36C | P10147 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-85-7843-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCL3 | SNV | Missense_Mutation | rs368462880 | c.89N>T | p.Pro30Leu | p.P30L | P10147 | protein_coding | deleterious(0.02) | possibly_damaging(0.751) | TCGA-CQ-6229-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |